Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司

Verified product status

AOD-9604 Development and Compounding Status

FDA’s December 2024 evaluation proposed not adding AOD-9604 free base or acetate to the 503A Bulks List, citing characterization, effectiveness and safety limitations. That compounding-list evaluation is not a product approval review and should not be rewritten as one.

Reviewed by QIANMIAO Technical TeamChecked 2026-09-02Primary regulatory / sponsor sources

Dated verification

What the reviewed sources establish

A regulatory proposal, advisory recommendation, clinical-development stage and marketing approval are kept as separate findings.

Approved drug status

No FDA-approved AOD-9604 finished drug identified in reviewed sources

FDA evaluation

503A proposal

FDA proposed not including AOD-9604 free base or acetate

December 2024 PCAC briefing

Clinical evidence

FDA review described limited evidence and studies that generally failed to show weight-reduction benefit versus placebo

FDA briefing review; not a new site efficacy analysis

Status timeline

Keep the date attached to the claim.

Later events do not retroactively change what an earlier source established. This timeline records the source context used for the current wording.

  1. AOD-9604 underwent clinical investigation; development history does not equal approval.

  2. FDA presented its 503A evaluation and proposed not adding the reviewed AOD-9604 forms.

  3. Status rechecked; no FDA-approved finished product is claimed.

Entity boundary

The name is not the approval.

Historical clinical investigation, a compounding nomination and catalog supply are different regulatory categories. None makes a research material an approved obesity medicine.

Research and regulatory information only. No clinical-use or dosing guidance.

Primary and technical sources

Records used for this guide

Sources are linked directly so the wording, date and scope can be checked independently.

  1. 01

    FDA Evaluation of AOD-9604-Related Bulk Drug Substances

    U.S. FDA. December 4, 2024 Pharmacy Compounding Advisory Committee briefing document.

    Source record
  2. 02

    Certain Bulk Drug Substances That May Present Significant Safety Risks

    U.S. FDA. Current compounding safety-information page.

    Source record

Knowledge center

Return to the full status tracker.